52476-87-6

Basic information

• Product Name: 2-Chloro-4-hydrazinopyrimidine
• Synonyms: 2-CHLORO-4-HYDRAZINOPYRIMIDINE;4(1H)-Pyrimidinone, 2-chloro-, hydrazone (9CI);2-chloro-4-hydrazinyl-pyrimidine;Pyrimidine, 2-chloro-4-hydrazinyl-;2-Chloro-4-hydrazinopyrimidine ,98%;(2-chloropyrimidin-4-yl)hydrazine;(2-chloro-4-pyrimidinyl)hydrazine
• CAS NO: 52476-87-6
• Molecular Formula: C₄H₅ClN₄
• Molecular Weight: 144.56
• Product Categories: PYRIMIDINE;Pyrazines, Pyrimidines & Pyridazines;Pyrimidine Derivertives;Pyrazines, Pyrimidines & Pyridazines;Heterocycle-Pyrimidine series
• Mol File: 52476-87-6.mol

Chemical Properties

• Boiling Point: 406.266 °C at 760 mmHg
• Flash Point: 199.503 °C
• Appearance: /
• Density: 1.53 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.684
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 3.50±0.70(Predicted)
• CAS DataBase Reference: 2-Chloro-4-hydrazinopyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-hydrazinopyrimidine(52476-87-6)
• EPA Substance Registry System: 2-Chloro-4-hydrazinopyrimidine(52476-87-6)

Safety Data

• Safety Statements: 24/25
• HazardClass: IRRITANT
• Hazardous Substances Data: 52476-87-6(Hazardous Substances Data)

Usage

Chemical Properties

White solid

InChI:InChI=1/C4H5ClN4/c5-4-7-2-1-3(8-4)9-6/h1-2H,6H2,(H,7,8,9)

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 302-01-2 hydrazine 

Downstream Products

• 923191-97-3 7-chloro-[1,2,4]triazolo[4,3-c]pyrimidine 
• 705941-11-3 C₁₁H₉ClN₄ 
• 22930-71-8 pyrimidin-4-ylhydrazine 
• 917757-17-6 1-(azepan-2-ylidene)-2-(2-chloropyrimidin-4-yl)hydrazine 

Relevant articles and documents

NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION

A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target. (I)

NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE

Disclosed are a nitrogenous heterocyclic compound, intermediates, a preparation method, a composition and use thereof. The nitrogenous heterocyclic compound in the present invention is as shown in formula I. The compound has a high inhibitory activity towards ErbB2 tyrosine kinase and a relatively good inhibitory activity towards human breast cancer BT-474 and human gastric cancer cell NCI-N87 which express ErbB2 at a high level, and at the same time has a relatively weak inhibitory activity towards EGFR kinase. Namely, the compound is a highly selective small-molecule inhibitor targeted at ErbB2, and hence it has a high degree of safety, and can effectively enlarge the safety window in the process of taking the drug.

De novo design approaches targeting an envelope protein pocket to identify small molecules against dengue virus

Dengue fever is a mosquito-borne viral disease that has become a major public health concern worldwide. This disease presents with a wide range of clinical manifestations, from a mild cold-like illness to the more serious hemorrhagic dengue fever and dengue shock syndrome. Currently, neither an approved drug nor an effective vaccine for the treatment are available to fight the disease. The envelope protein (E) is a major component of the virion surface. This protein plays a key role during the viral entry process, constituting an attractive target for the development of antiviral drugs. The crystal structure of the E protein reveals the existence of a hydrophobic pocket occupied by the detergent n-octyl-β-d-glucoside (β-OG). This pocket lies at the hinge region between domains I and II and is important for the low pH-triggered conformational rearrangement required for the fusion of the virion with the host's cell. Aiming at the design of novel molecules which bind to E and act as virus entry inhibitors, we undertook a de novo design approach by “growing” molecules inside the hydrophobic site (β-OG). From more than 240000 small-molecules generated, the 2,4 pyrimidine scaffold was selected as the best candidate, from which one synthesized compound displayed micromolar activity. Molecular dynamics-based optimization was performed on this hit, and thirty derivatives were designed in silico, synthesized and evaluated on their capacity to inhibit dengue virus entry into the host cell. Four compounds were found to be potent antiviral compounds in the low-micromolar range. The assessment of drug-like physicochemical and in vitro pharmacokinetic properties revealed that compounds 3e and 3h presented acceptable solubility values and were stable in mouse plasma, simulated gastric fluid, simulated intestinal fluid, and phosphate buffered saline solution.

Compound and organic electroluminescent device

The invention provides a compound, which is shown as a following general formula (I) or (II) in the specification, wherein, X is selected from CR 4 or N; R 1 to R 4 are respectively and independentlyselected from hydrogen, C1-C10 alkyl groups, substituted or unsubstituted C5 -C60 aryl or heteroaryl groups, the substituent of aryl or heteroaryl groups is selected from deuterium, fluorine, methyl group, methoxy group, cyano group, phenyl group, biphenyl group, naphthyl group, phenanthryl group, and substituted or unsubstituted anthracyl group, the substituent of the anthracyl group is selectedfrom the group consisting of phenyl, biphenyl, terphenyl, naphthyl, and phenanthryl; and a dotted line and Cy in the general formula (II) represent a five- or six-membered aromatic or heteroaromatic ring fused to a pyrimidine ring. The compound can be used in an organic electroluminescent device. The invention also provides an organic electroluminescent device comprising the above compound.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

2, 6-DISUBSTITUTED PYRIDINES AND 2, 4-DISUBSTITUTED PYRIMIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS

Disclosed are compounds of formula (I): wherein n represents 1 or 2; each R1 independently represents halo or trifluoromethyl; wherein halo represents fluoro, chloro or bromo; R2 represents hydrogen or C1-3alkyl; X represents N or CH; wherein -Z- represents a group selected from: (A), (B) or (C), wherein R3 represents trifluoromethyl or C1-3alkyl; and R4 represents hydrogen, trifluoromethyl or C1-3alkyl; with the proviso that where Z represents a thiophene group and X represents N, R2 cannot represent C1-3alkyl; and when X represents CH, -Z- can additionally represent a group selected from: (D) or (E) or salts thereof which activate soluble guanylate cyclase (sGC) pharmaceutical compositions containing them, their use is medicine, and processes for their preparation.

Design, synthesis and biological evaluation of novel 6,7,8,9-tetrahydro-2- (2-aryloxypyrimidin-4-yl)-2H-[1,2,4]triazolo[4,3-a]azepin-3(5H)-ones

A series of novel 6,7,8,9-tetrahydro-2-(2-aryloxypyrimidin-4-yl)-2H-[1,2,4] triazolo[4,3-a]azepin-3(5H)-ones were designed and efficiently synthesized. Their structures were determined by IR, 13C and 1H NMR, mass spectroscopy, and elemental analysis. These compounds were screened for herbicidal activities against rape and barnyard grass. Compounds 5a-5f and 5m exhibited moderate herbicidal activity against rape. In addition, the synthesis of the intermediate 1-(azepan-2-ylidene)-2-(2-chloropyrimidin-4-yl)-hydrazine (3) was studied and the reason for the low yield in the initial procedure is discussed as well.

Development of N-2,4-pyrimidine-N-phenyl-N′-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-α) synthesis. Part 1

A new class of tumor necrosis factor alpha (TNF-α) synthesis inhibitors based on an N-2,4-pyrimidine-N-phenyl-N′-phenyl urea scaffold is described. Many of these compounds showed low-nanomolar activity against lipopolysaccharide stimulated TNF-α productio